Navigation Links
Angioslide Announces First Successful Below-The-Knee Procedures in the US
Date:7/11/2012

CAESAREA, Israel, July 11, 2012 /PRNewswire/ --

Angioslide Ltd., a provider of Embolic Capture Angioplasty solutions, today announced the successful deployment of a 3X100mm PROTEUS device for treating Peripheral Artery Disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, IN. Accommodating a 0.014" guide-wire, the new device allows physician to perform a PTA revascularization in BTK vessels while capturing and removing embolic particles.

"With PROTEUS having been successfully used to treat lesions in the SFA (superficial femoral artery), I had the opportunity to deploy the device in BTK procedures," said Dr. Prakash Makam of Community Hospital (Munster, IN). "It is an effective, easy to use tool that provides an alternative for removal of embolic material, including micro particles, that could compromise downstream vasculature flow and perfusion to the foot. This is especially important when treating high-risk, diabetic and critical limb ischemia (CLI) patients."

Angioslide's proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention.  Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity. When retrieved through the sheath, PROTEUS removes the captured material from the body.

"We are excited to provide a solution for capture and removal of embolic debris for below-the-knee intervention, where the clinical consequences of emboli are amplified by small vessel diameter," said Lihu Avitov, CEO, Angioslide. "The Current set of tools available on the market for BTK intervention are suboptimal, and we look forward to meeting this important clinical need. With the successful completion of our first cases in the US, we will introduce our product to a wider number of centers."  

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic suction mechanism. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic removal solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colorado. For more information visit our website at http://www.angioslide.com

Contact:

Shira Doron
Marketing Director
Mobile: +972-54-9011134
Email: shirad@angioslide.com


'/>"/>
SOURCE Angioslide Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
2. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
3. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
4. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
5. Genova Diagnostics, Inc. Announces the Acquisition of Metametrix, Inc.
6. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
7. Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
8. Elsevier Announces New Editor-In-Chief for Neurobiology of Learning and Memory
9. Express Scripts Holding Company Announces Second Quarter 2012 Earnings Conference Call
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Mesa Labs Announces New Logo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals ... the field of eating disorders, announces the opening of early registration for the ... at the Omni Resort at ChampionsGate. , The annual iaedp™ Symposium ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):